title: HTR2C polymorphisms, olanzapine-induced weight gain and antipsychotic-induced metabolic syndrome in schizophrenia patients: a meta-analysis.
abstract: OBJECTIVE
  To conduct meta-analyses of all published association studies on the HTR2C -759C/T (rs3813829) polymorphism and olanzapine-induced weight gain in schizophrenia patients and on the HTR2C -759C/T, -697G/C (rs518147) and rs1414334:C> G polymorphisms and olanzapine/clozapine/risperidone-induced metabolic syndrome in schizophrenia patients.
  
  
  METHODS
  Eligible studies were identified by searching PubMed and Web of Science databases. Meta-analyses were performed using Cochrane Review Manager (RevMan, version 5.2) to calculate the pooled odds ratio (OR) and its corresponding 95% confidence interval (CI).
  
  
  RESULTS
  Our meta-analyses revealed both a significant positive association between the rs1414334 C allele and olanzapine/clozapine/risperidone-induced metabolic syndrome and a marginally significant positive association between the -697C allele and the induced metabolic syndrome in schizophrenia patients, but no significant association between the -759C/T polymorphism and the induced metabolic syndrome in schizophrenia patients. Our analysis further revealed a pronounced trend toward a significant negative association between the -759T allele and high olanzapine-induced weight gain and a trend toward a significant positive association between the -759C allele and high olanzapine-induced weight gain in Caucasian schizophrenia patients.
  
  
  CONCLUSIONS
  Our results support that HTR2C polymorphisms play a role in antipsychotic-induced metabolic disturbance. More association studies are needed to further elucidate association of different HTR2C polymorphisms and antipsychotic-induced metabolic disturbance.
authors.affiliation: Department of Geriatrics, The Fourth People's Hospital of Urumqi City , Urumqi, Xinjiang Province , P. R. China.
authors.forename: Xiaojie
authors.initials: X
authors.lastname: Ma
authors.forename: Tuerxun
authors.initials: T
authors.lastname: Maimaitirexiati
authors.forename: Rong
authors.initials: R
authors.lastname: Zhang
authors.forename: Xueping
authors.initials: X
authors.lastname: Gui
authors.forename: Wenhui
authors.initials: W
authors.lastname: Zhang
authors.forename: Guozheng
authors.initials: G
authors.lastname: Xu
authors.forename: Gang
authors.initials: G
authors.lastname: Hu
mesh_terms: D000483:Alleles; D014150:Antipsychotic Agents / Q000009:adverse effects*; D001569:Benzodiazepines / Q000009:adverse effects*; D003024:Clozapine / Q000009:adverse effects; D005260:Female; D056726:Genetic Association Studies; D006801:Humans; D008297:Male; D024821:Metabolic Syndrome / Q000139:chemically induced* / Q000150:complications / Q000235:genetics*; D000077152:Olanzapine; D020641:Polymorphism, Single Nucleotide / Q000235:genetics; D044405:Receptor, Serotonin, 5-HT2C / Q000235:genetics*; D018967:Risperidone / Q000009:adverse effects; D012559:Schizophrenia / Q000150:complications* / Q000188:drug therapy* / Q000235:genetics; D015430:Weight Gain / Q000187:drug effects* / Q000235:genetics
chemical_list: D014150:Antipsychotic Agents; D044405:Receptor, Serotonin, 5-HT2C; D001569:Benzodiazepines; D003024:Clozapine; D018967:Risperidone; D000077152:Olanzapine
keywords: HTR2C polymorphism; antipsychotic; metabolic syndrome; schizophrenia; weight gain